Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02416206 · ClinicalTrials.gov registry record · Phase 2
High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma
A Phase 2 study, sponsored by Northside Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT02416206 is a Phase 2 study that has completed, run by Northside Hospital. The registered enrollment target is 65 participants.
The verdict
NCT02416206, a Phase 2 study, has completed, sponsored by Northside Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
High-dose chemotherapy and autologous stem cell transplantation (ASCT) as part of the up-front treatment of patients with multiple myeloma has been associated with improved disease-free and overall survival in multiple large randomized controlled trials. Following 3-6 cycles of standard induction therapy with biologic agents, consolidation with high dose Melphalan and ASCT has become the standard-of-care approach for fit myeloma patients up to 70 years of age. Single-agent high-dose Melphalan (200mg/m2) is currently the standard-of-care preparative regimen prior to autologous transplant in Myeloma. Historical studies utilizing Busulfan- or Total Body Irradiation-based preparative regimens have yielded similar results to single-agent Melphalan with higher toxicity.
Interventions
- DRUG BeEAM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2015-04-27 |
| Est. Completion | 2021-04-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02416206
The ClinicalTrials.gov registry entry for NCT02416206 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northside Hospital, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BeEAM is the first listed.
NCT02416206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02416206 about?
NCT02416206 is a clinical study titled "High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma". High-dose chemotherapy and autologous stem cell transplantation (ASCT) as part of the up-front treatment of patients with multiple myeloma has been associated with improved disease-free and overall survival in multiple large randomized controlled trials. Following 3-6 cycles of standard induction th...
What is the current status of trial NCT02416206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2015-04-27. Estimated completion is 2021-04-21.
What interventions are being tested in trial NCT02416206?
The interventions under investigation include: BeEAM (DRUG).
Who is sponsoring clinical trial NCT02416206?
This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.